Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefazolin + metronidazole + lidocaine + epinephrine + sodium bicarbonate
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
This is a multi-component formulation used in Tumescent Anesthesia Antibiotic Delivery (TAAD), primarily studied for the prevention of surgical site infections (SSI) and biofilms in colorectal surgery. The solution consists of two antibiotics—cefazolin (a first-generation cephalosporin) and metronidazole (an anaerobic-active nitroimidazole)—dissolved in a tumescent lidocaine anesthesia (TLA) base. The TLA base typically contains lidocaine (local anesthetic), epinephrine (vasoconstrictor to prolong local effect and reduce systemic absorption), and sodium bicarbonate (buffer to reduce injection pain) in physiologic saline. By delivering high concentrations of antibiotics directly into the subcutaneous tissue, TAAD aims to achieve superior local tissue levels compared to standard intravenous administration, potentially reducing the risk of incisional infections.
- Other names
- Tumescent Anesthesia Antibiotic Delivery solutionTAAD solution
02
Targets
PBP (Penicillin-binding protein family)AR (Adrenergic receptors)DNA in anaerobic bacteria/protozoaNaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on cefazolin + metronidazole + lidocaine + epinephrine + sodium bicarbonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefazolin + metronidazole + lidocaine + epinephrine + sodium bicarbonate.